LIAM, Chong Kin
YEW, Chian Yih
PANG, Yong Kek
WONG, Chee Kuan
POH, Mau Ern
TAN, Jiunn Liang
SOO, Chun Ian
LOH, Thian Chee
CHIN, Ka Kiat
MUNUSAMY, Vijayan
LIAM, Yong Sheng
IBRAHIM, Nur Husna
Article History
Received: 19 November 2022
Accepted: 6 July 2023
First Online: 14 July 2023
Declarations
:
: All methods were carried out in accordance with relevant guidelines and regulations. The study was approved by the University of Malaya Medical Centre ethics committee. Informed consent was deemed unnecessary by the the University of Malaya Medical Centre ethics committee.
: Not applicable.
: Chong Kin LIAM -Received research grants from AstraZeneca and Boehringer Ingelheim; and received honoraria and fees for lectures and advisory board meetings from AstraZeneca, Boehringer Ingelheim, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche, and Zeullig Pharma.Yong Kek PANG - Received honoraria and fees for lectures and advisory board meetings from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Pfizer, and Roche.Jiunn Liang TAN - Received honoraria and fees for lectures and advisory board meetings from Merck Sharp & Dohme, Novartis, and Pfizer.The other authors do not have any conflict of interest to declare.